Related references
Note: Only part of the references are listed.An oncogenic axis of STAT-mediated BATF3 upregulation causing MYC activity in classical Hodgkin lymphoma and anaplastic large cell lymphoma
A. Lollies et al.
LEUKEMIA (2018)
Cell-Cycle Regulation Accounts for Variability in Ki-67 Expression Levels
Michal Sobecki et al.
CANCER RESEARCH (2017)
Hodgkin lymphoma: Pathology and biology
Stephan Mathas et al.
SEMINARS IN HEMATOLOGY (2016)
CD30 and CD30-Targeted Therapies in Hodgkin Lymphoma and Other B cell Lymphomas
Geetika Bhatt et al.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2016)
Reed-Sternberg cell-derived lymphotoxin-α activates endothelial cells to enhance T-cell recruitment in classical Hodgkin lymphoma
Chee Wai Fhu et al.
BLOOD (2014)
The oncogenic JUNB/CD30 axis contributes to cell cycle deregulation in ALK plus anaplastic large cell lymphoma
Vassilis Atsaves et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
c-JUN N-terminal kinase (JNK) is activated and contributes to tumor cell proliferation in classical Hodgkin lymphoma
Vasiliki Leventaki et al.
HUMAN PATHOLOGY (2014)
Expression of granzyme B sensitizes ALK plus ALCL tumour cells to apoptosis-inducing drugs
Joel D. Pearson et al.
MOLECULAR CANCER (2014)
Mapping of transcription factor motifs in active chromatin identifies IRF5 as key regulator in classical Hodgkin lymphoma
Stephan Kreher et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
The microenvironment in classical Hodgkin lymphoma: An actively shaped and essential tumor component
Yuxuan Liu et al.
SEMINARS IN CANCER BIOLOGY (2014)
PU.1 is a potent tumor suppressor in classical Hodgkin lymphoma cells
Hiromichi Yuki et al.
BLOOD (2013)
Role of early B-cell factor 1 (EBF1) in Hodgkin lymphoma
V. Bohle et al.
LEUKEMIA (2013)
FOXO1 is a tumor suppressor in classical Hodgkin lymphoma
Linka Xie et al.
BLOOD (2012)
Constitutive AP-1 Activity and EBV Infection Induce PD-L1 in Hodgkin Lymphomas and Posttransplant Lymphoproliferative Disorders: Implications for Targeted Therapy
Michael R. Green et al.
CLINICAL CANCER RESEARCH (2012)
Multiple degradation pathways regulate versatile CIP/KIP CDK inhibitors
Natalia G. Starostina et al.
TRENDS IN CELL BIOLOGY (2012)
MiR-17/106b seed family regulates p21 in Hodgkin's lymphoma
Johan H. Gibcus et al.
JOURNAL OF PATHOLOGY (2011)
Targeted Repression of Overexpressed CD30 Downregulates NF-κB and ERK1/2 Pathway in Hodgkin Lymphoma Cell Lines
Mariko Watanabe et al.
ONCOLOGY RESEARCH (2011)
High Cleavage Efficiency of a 2A Peptide Derived from Porcine Teschovirus-1 in Human Cell Lines, Zebrafish and Mice
Jin Hee Kim et al.
PLOS ONE (2011)
Mechanisms of aberrant GATA3 expression in classical Hodgkin lymphoma and its consequences for the cytokine profile of Hodgkin and Reed/Sternberg cells
Jens Stanelle et al.
BLOOD (2010)
CD30(+) lymphoproliferative disorders
Laurence de Leval et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy
Isabel M. Chu et al.
NATURE REVIEWS CANCER (2008)
The selectivity of protein kinase inhibitors: a further update
Jenny Bain et al.
BIOCHEMICAL JOURNAL (2007)
The oncoprotein NPM-ALK of anaplastic large-cell lymphoma induces JUNB transcription via ERK1/2 and JunB translation via mTOR signaling
Philipp B. Staber et al.
BLOOD (2007)
NPM-ALK oncogenic kinase promotes cell-cycle progression through activation of JNK/cJun signaling in anaplastic large-cell lymphoma
Vasiliki Leventaki et al.
BLOOD (2007)
The AP1-dependent secretion of galectin-1 by Reed - Sternberg cells fosters immune privilege in classical Hodgkin lymphoma
Przemyslaw Juszczynski et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
c-Jun expression and activation are restricted to CD30(+) lymphoproliferative disorders
Elias Drakos et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2007)
Uses for JNK: the many and varied substrates of the c-Jun N-terminal kinases
Marie A. Bogoyevitch et al.
MICROBIOLOGY AND MOLECULAR BIOLOGY REVIEWS (2006)
Fos/AP-1 proteins in bone and the immune system
EF Wagner et al.
IMMUNOLOGICAL REVIEWS (2005)
The Epstein-Barr virus protein, latent membrane protein 2A, co-opts tyrosine kinases used by the T cell receptor
RJ Ingham et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
JunB expression is a common feature of CD30+lymphomas and lymphomatoid papulosis
GZ Rassidakis et al.
MODERN PATHOLOGY (2005)
JunB induced by constitutive CD30-extracellular signal-regulated kinase 1/2 mitogen-activated protein kinase signaling activates the CD30 promoter in anaplastic large cell lymphoma and Reed-Sternberg cells of Hodgkin lymphoma
M Watanabe et al.
CANCER RESEARCH (2005)
Expression of the T-cell transcription factors, GATA-3 and T-bet, in the neoplastic cells of Hodgkin lymphomas
C Atayar et al.
AMERICAN JOURNAL OF PATHOLOGY (2005)
AP-1 mediated relief of repressive activity of the CD30 promoter microsatellite in Hodgkin and Reed-Sternberg cells
M Watanabe et al.
AMERICAN JOURNAL OF PATHOLOGY (2003)
Amplification and overexpression of JUNB is associated with primary cutaneous T-cell lymphomas
X Mao et al.
BLOOD (2003)
Aberrantly expressed c-Jun and JunB are a hallmark of Hodgkin lymphoma cells, stimulate proliferation and synergize with NF-κB
S Mathas et al.
EMBO JOURNAL (2002)
Loss of B cell identity correlates with loss of B cell-specific transcription factors in Hodgkin/Reed-Sternberg cells of classical Hodgkin lymphoma
CB Hertel et al.
ONCOGENE (2002)
AP-1 as a regulator of cell life and death
E Shaulian et al.
NATURE CELL BIOLOGY (2002)
Signal transducer and activator of transcription 6 is frequently activated in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma
BF Skinnider et al.
BLOOD (2002)
Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method
KJ Livak et al.
METHODS (2001)
The transcription factor PU.1, necessary for B-cell development is expressed in lymphocyte predominance, but not classical Hodgkin's Disease
E Torlakovic et al.
AMERICAN JOURNAL OF PATHOLOGY (2001)
STAT3 is constitutively activated in Hodgkin cell lines
D Kube et al.
BLOOD (2001)
Close encounters of many kinds: Fos-Jun interactions that mediate transcription regulatory specificity
Y Chinenov et al.
ONCOGENE (2001)
AP-1 in cell proliferation and survival
E Shaulian et al.
ONCOGENE (2001)
Share Paper
